Biohaven Corp (BHVN): Price to Earnings Adjusted for Growth Rate
Biohaven Ltd. minimizes risks through a broad spectrum of CNS therapies, relying on a stable staff of dedicated neurobiologists. The normalized PEG ratio visualizes the relationship between valuation and business growth rates, where 0.00 indicates the current level. The efficiency of discovering new drug formulas is ensured here by the implementation of automated bioinformatic target analysis systems.
Analytical breakdowns for Biohaven Ltd. (BHVN)
- price and consensus price forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Equity Biohaven Ltd.|BHVN - Long-Term Debt to Capital|Current Liabilities to Capital biohavenpharma.com|BHVN - Company Debts|Debt to Book Value Ratio Biohaven Pharmaceutical|BHVN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Biohaven|Quick Liquidity biohavenpharma.com
- earnings and valuation multiples information:
BHVN - Net Income|Future Net Profit Biohaven Ltd.|BHVN - P/E Multiple|Price to Future Earnings Ratio Biohaven Corp|BHVN - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Biohaven Pharmaceutical|BHVN - Operating profit EBITDA|Earnings per share for the last twelve months Biohaven|BHVN - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months biohavenpharma.com|BHVN - Net earnings per share growth this year|Net earnings per share growth forecast for next year Biohaven Ltd.
Fundamental company analysis:Biohaven Ltd (BHVN)
The PEG ratio compares the current P/E multiple to the earnings growth rate, allowing investors to determine if they are overpaying for future business expansion. By analyzing the fair value PEG dynamics, one can assess the efficiency of capturing niches in neurological disorder therapies via the Kv7 platform, revealing the undervaluation of Biohaven Ltd. (BHVN) relative to the scaling pace of its innovative pipeline.
Who Biohaven Ltd. competes with
Growth-Adjusted Market Cap to Net Income Biogen Inc|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|Regencell Corp (RGC) - Price to Earnings Adjusted for Growth Rate|Axsome Therapeutics - PEG Multiple|Growth-Adjusted Payback Ratio ACAD (acadia-pharm.com)|XENE: PEG Multiple|Viking Therapeutics Inc (VKTX) - PEG Multiple|Price/Earnings to Growth Multiple SUPN|Price/Earnings to Growth Ratio CPRX|PEG Multiple DNLI|HRMY - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Growth-Adjusted P/E Ratio|PRAX: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio AVXL (Anavex Life Sciences Corp)|CeriBell, Inc. (CBLL) - Price/Earnings to Growth Ratio|PRTA (Prothena) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple ALEC|ANNX (Annexon Biosciences) - Company Value to Earnings Growth Ratio|PEG Multiple OMER|Neurogene Therapeutics - Growth-Adjusted P/E Ratio|AC Immune - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income voyagertherapeutics.com (VYGR)|Neumora Therapeutics, Inc. - PEG Multiple|SCLX: Price/Earnings to Growth Ratio|TVGN: PEG Multiple|Alpha Cognition Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple CGTX|Price/Earnings to Growth Ratio IKT|Price/Earnings to Growth Ratio Cassava Sciences (SAVA)|assertiotx.com - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Coya Therapeutics COYA|VTGN: Growth-Adjusted P/E Ratio|Ovid Rx - PEG Multiple|Price to Earnings Adjusted for Growth Rate acumenpharm.com|CRVO (CervoMed) - Price/Earnings to Growth Multiple|Alterity Therapeutics Limited (ATHE) - PEG Multiple|Price/Earnings to Growth Ratio Clene Inc|PEPG: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Jupiter Neurosciences Inc (JUNS)|RLMD - Price to Earnings Adjusted for Growth Rate|PEG Multiple ANVS (Annovis Bio)|Grace Therapeutics Inc - Price/Earnings to Growth Ratio|Firefly Neuroscience Inc - PEG Multiple|Growth-Adjusted Market Cap to Net Income Klotho Neurosciences Inc KLTO|neurosense-tx.com (NRSN) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate revivapharma.com (RVPH)|MTVA (MetaVia Inc.) - PEG Multiple|NRXS: Growth-Adjusted Payback Ratio|PEG Multiple HSDT|PEG Multiple passagebio.com (PASG)|Neuphoria Therapeutics - Price/Earnings to Growth Multiple|minervaneurosciences.com - Price/Earnings to Growth Ratio|Athira Pharma - PEG Multiple|Price to Earnings Adjusted for Growth Rate Addex Therapeutics Ltd.|alzamend.com (ALZN) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio CYCN|Price/Earnings to Growth Multiple PTIX|KTTA: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Cortigent, Inc. (CRGT)|Price/Earnings to Growth Ratio ATXI (Avenue Therapeutics Inc.)|Brainstorm Cell Therapeutics, Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio CARA (Cara Therapeutics Inc)|Chromocell Therapeutics - PEG Multiple|ELYM (Eliem Therapeutics) - Growth-Adjusted P/E Ratio|ITCI (intracellulartherapies.com) - Price/Earnings to Growth Multiple|LBPH - Growth-Adjusted Market Cap to Net Income|MRNS (Marinus) - PEG Multiple|Price/Earnings to Growth Ratio NKGN|PEG Multiple NRBO|SAGE (sagerx.com) - Growth-Adjusted Payback Ratio|Synaptogenix - Price/Earnings to Growth Multiple|Trevena Inc. - Price/Earnings to Growth Ratio|VIGL - Price/Earnings to Growth Ratio|WENA (Anew Medical Inc.) - Growth-Adjusted P/E Ratio|Cerevel Therapeutics (CERE) - Price/Earnings to Growth Ratio
